Literature DB >> 35099674

Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.

Yu-Ping Yuan1, Ping Yuan2, Yi-Liang Su3, Rong Jiang2, Rui Zhang2, Jing He2, Hong-Ling Qiu2, Ci-Jun Luo2, Jin-Ming Liu2, Su-Gang Gong4, Lan Wang5, Qin-Hua Zhao6.   

Abstract

INTRODUCTION: Systemic sclerosis (SSc) is associated with interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH). This study aimed to explore the prevalence, clinical features, hemodynamic characteristics and prognosis of different severity of ILD in a cohort of patients with SSc-associated precapillary pulmonary hypertension (SSc-PH) and investigate the differences between SSc-PAH and idiopathic pulmonary arterial hypertension (IPAH) patients.
METHOD: SSc-PH patients and IPAH patients, admitted to Shanghai Pulmonary Hospital (August 1, 2008-January 31, 2020) and diagnosed by right-sided heart catheterization (RHC) or echocardiography, were retrospectively included. SSc-PH patients had a baseline chest high-resolution computed tomography (HRCT), and PH classification was based on the extent of ILD. Clinical, pulmonary function, hemodynamic characteristics and survival data were extracted.
RESULTS: The study included 45 SSc-PH patients (60% had coexisting ILD and 77.8% were SSc-Group 1 PH/SSc-PAH [without ILD or with mild ILD], 22.2% were SSc-Group 3 PH/SSc-PH with severe ILD) and 52 IPAH patients. SSc-PH with ILD had lower arterial oxygen partial pressure (PaO2) than those without ILD. Hemodynamic characteristics and survival rates were comparable between SSc-PAH with mild ILD and those without ILD. SSc-Group 3 PH had lower pulmonary vascular resistance (PVR) and more severe restrictive ventilatory dysfunction than SSc-Group 1 PH, but the survival rate was equally poor. SSc-PAH had a poorer prognosis than IPAH patients despite the better hemodynamic characteristics.
CONCLUSIONS: ILD was common in SSc-PH patients. Careful phenotyping of PH in SSc-PH patients is very important as it is imperative to recognize its impact on clinical course, treatment and survival. KEY POINTS: • ILD was common in Chinese SSc-PH patients. • SSc-PH patients with ILD had lower PaO2 than those without ILD. • Hemodynamic characteristics and survival rates were similar in SSc-PAH patients with mild ILD and those without ILD. • Patients in SSc-Group 3 PH had lower pulmonary vascular resistance (PVR) and more severe restrictive ventilatory dysfunction than those in SSc-Group 1 PH, but the survival rate was equally poor. SSc-PAH patients had a poorer prognosis than IPAH patients despite their better hemodynamic characteristics.
© 2022. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Hemodynamic; Interstitial lung disease; Pulmonary hypertension; Survival; Systemic sclerosis

Mesh:

Year:  2022        PMID: 35099674     DOI: 10.1007/s10067-021-06016-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  38 in total

1.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Respir J       Date:  2015-08-29       Impact factor: 16.671

2.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 4.  Definitions and diagnosis of pulmonary hypertension.

Authors:  Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 5.  Updated clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

6.  Mapping and predicting mortality from systemic sclerosis.

Authors:  Muriel Elhai; Christophe Meune; Marouane Boubaya; Jérôme Avouac; Eric Hachulla; Alexandra Balbir-Gurman; Gabriela Riemekasten; Paolo Airò; Beatriz Joven; Serena Vettori; Franco Cozzi; Susanne Ullman; László Czirják; Mohammed Tikly; Ulf Müller-Ladner; Paola Caramaschi; Oliver Distler; Florenzo Iannone; Lidia P Ananieva; Roger Hesselstrand; Radim Becvar; Armando Gabrielli; Nemanja Damjanov; Maria J Salvador; Valeria Riccieri; Carina Mihai; Gabriella Szücs; Ulrich A Walker; Nicolas Hunzelmann; Duska Martinovic; Vanessa Smith; Carolina de Souza Müller; Carlo Maurizio Montecucco; Daniela Opris; Francesca Ingegnoli; Panayiotis G Vlachoyiannopoulos; Bojana Stamenkovic; Edoardo Rosato; Stefan Heitmann; Jörg H W Distler; Thierry Zenone; Matthias Seidel; Alessandra Vacca; Ellen De Langhe; Srdan Novak; Maurizio Cutolo; Luc Mouthon; Jörg Henes; Carlo Chizzolini; Carlos Alberto von Mühlen; Kamal Solanki; Simona Rednic; Lisa Stamp; Branimir Anic; Vera Ortiz Santamaria; Maria De Santis; Sule Yavuz; Walter Alberto Sifuentes-Giraldo; Emmanuel Chatelus; Jiri Stork; Jacob van Laar; Esthela Loyo; Paloma García de la Peña Lefebvre; Kilian Eyerich; Vanesa Cosentino; Juan Jose Alegre-Sancho; Otylia Kowal-Bielecka; Grégoire Rey; Marco Matucci-Cerinic; Yannick Allanore
Journal:  Ann Rheum Dis       Date:  2017-08-23       Impact factor: 19.103

Review 7.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

8.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 9.  Systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Neal F Chaisson; Paul M Hassoun
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

Review 10.  Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course.

Authors:  Mike O Becker; Gabriela Riemekasten
Journal:  Expert Rev Clin Immunol       Date:  2015-12-02       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.